TMU Biomed Accelerator Partners with Singapore to Support Startup Expansion into Southeast Asia

This year, the Accelerator also launched a partnership with A.L.I.C.E (Alice Lee Innovation Centre of Excellence), an innovation center under Singapore’s SingHealth, to support participating startups in expanding into the Southeast Asian market.

The event brought together key players from the biotech and healthcare industries, including Far East Bio-Tec. Co. Ltd. (FEBICO), Leadtek Biomed Inc., and Might Electronics Co., Ltd., and international organizations such as Belgian Office Taipei and PricewaterhouseCoopers Accounting Firm (PwC). Additionally, Dr. Cheong May Anne, Co-Director at A.L.I.C.E, was invited to share insights into Singapore’s innovation ecosystem and resources.

Biomed Startup Ecosystem 2.0

Since its establishment in 2018, the TMU Biomed Accelerator has supported over 100 startups and established partnerships with well-known international organizations, such as AstraZeneca, Stanford Biodesign, and Berkeley SkyDeck. This year’s program attracted innovative startups from Taiwan, Singapore, Japan, South Korea, Belgium, and Canada, reflecting the Accelerator’s growing global reach and influence.

This year’s TMU PoC Program welcomed eleven startups from Taiwan and abroad advancing AI and non-invasive medical technologies.

• Dermatoo (Belgium) – Radical innovations in wound care management that enhance clinical decision-making and wound assessment.
• Ducolege Biotechnology Co., Ltd. (Taiwan) – Development of Extre2Cold to extract high-activity collagen from fish skin to create active wound dressings.
• Enlighten Co., Ltd. (Taiwan) – A biotech company focusing on cancer stem cell immunotherapy to address cancer recurrence and metastasis.
• E3A Healthcare (Singapore) – Designs non-invasive medical devices for fetal monitoring, neonatal jaundice management, and endometriosis therapy.
• fcuro Inc. (Japan) – Applies artificial intelligence to full-body CT imaging for accurate lesion identification.
• mesoView Co., Ltd. (Taiwan) – Develops NLOM imaging systems featuring a fine millimeter-scale field of view, submicron imaging resolution, and faster scanning speeds..
• NEAR Brain (South Korea) – An AI-driven healthcare startup specializing in cerebrovascular diagnostics, through 3D reconstruction of brain vessels from MRI/MRA to predict blood flow and aid neurosurgical diagnosis and treatment.
• PragmaClin Research Inc. (Canada) – Utilizes real-time motion capture and AI to monitor and evaluate Parkinson’s disease symptoms.
• StarBIA Meditek Co., Ltd. (Taiwan) – Applies Bioelectrical Impedance Analysis (BIA) technology to body composition monitoring systems and mobile health applications.
• Taiwan Medical Electronics Co., Ltd. (Taiwan) – Develops iontophoresis and localized drug delivery technologies for treating palmar hyperhidrosis.
• VitruvianMD (Singapore) – A medtech company offering AI-powered sperm selection solutions designed to enhance outcomes in male infertility diagnosis.

Accelerating the Introduction of Biomedical Innovation into Clinical Practices

TMU President Mai-Szu Wu stated that TMU leverages its One Campus system to support startup teams in conducting clinical validation and business development. By partnering with international medical universities and hospitals, TMU aims to accelerate the translation of innovative biomedical technologies into real-world clinical applications.

TMU Executive Vice President Kang-Yun Lee, pointed out that TMU’s three affiliated hospitals have completed the upgrade of the Hospital Information System to version 3.0, positioning them as experimental hubs for AI-driven medical innovation. Moreover, technology rendering is continuously promoted to improve the quality of precision healthcare services. Since 2024, the university has actively expanded into the Asian healthcare market through collaboration with Tohoku University in Japan, participation in the government’s Multi-country, Multi-center Medical Cooperation Program, and supporting startup teams entering Southeast Asian markets.

Dr. Yu-Jen Hsiao, Dean of the Office of Business Development at TMU, indicated that the Biomed Startup Ecosystem 1.0 is now advancing toward version 2.0. Key objectives include developing new innovation hubs, expanding commercialization channels, launching dedicated investment funds, and integrating academic, clinical, and industry resources to accelerate the translation of innovative technologies into practical applications.